Article

Aromasin Reduces Breast Cancer Risk in Healthy Older Women

Aromasin (exemestane) provides alternative option for postmenopausal women in breast cancer prevention.

The highest risk factor for breast cancer is age, especially after 60 and after menopause, which is why researchers have been searching for chemoprevention that can help lower the risk of one of the most common cancers in women. While tamoxifen, and more recently Evista (raloxifene), have shown great improvement in reducing the risk of invasive breast cancer (by about 50 percent), only a small percentage of women at high risk take tamoxifen to reduce breast cancer risk, primarily due to rare but serious side effects, including stroke and blood clots.

Lead investigator of the trial, Paul Goss, MD, PhD, of Massachusetts General Hospital, hopes to change that with the news that Aromasin (exemestane), an aromatase inhibitor used to prevent breast cancer recurrence, lowers the relative risk of primary invasive breast cancer by 65 percent—a greater effect than tamoxifen and Evista, and without the severe side effects. Even when non-invasive cancers (ductal carcinoma in situ) were included, the rate was a 53 percent relative risk reduction. Many symptoms were the same in the Aromasin arm versus the placebo arm, including hot flashes and fatigue.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
Image of two doctors with text.
Imiage of two doctors with text.
Enhertu with Perjeta nearly doubled progression-free survival versus standard treatment in metastatic HER2-positive breast cancer, study shows.
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Image of woman.